Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ez-PAVE: Ezetimibe Combination vs Statin Monotherapy in ASCVD
NCT04626973Completed
- Sponsor
- Yonsei University
- Start
- Jan 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ezetimibe in atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Yonsei University. Primary endpoint: Clinical outcomes by different lipid-lowering therapy at 3 years. Started Jan 2021; status: completed.
02
Drugs
ezetimibe
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT04626973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626973.